• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Mild Cognitive Impairment - Pipeline Review, H2 2012 Product Image

Mild Cognitive Impairment - Pipeline Review, H2 2012

  • Published: October 2012
  • 108 pages
  • Global Markets Direct

Mild Cognitive Impairment – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Mild Cognitive Impairment - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Mild Cognitive Impairment, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mild Cognitive Impairment. Mild Cognitive Impairment - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Mild Cognitive Impairment.
- A review of the Mild Cognitive Impairment products under READ MORE >

2
List of Tables 7
List of Figures 8
Introduction 9
REPORT COVERAGE 9
Mild Cognitive Impairment Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Mild Cognitive Impairment 11
Mild Cognitive Impairment Therapeutics under Development by Companies 13
Mild Cognitive Impairment Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 17
Comparative Analysis 17
Mid Clinical Stage Products 18
Comparative Analysis 18
Early Clinical Stage Products 19
Comparative Analysis 19
Discovery and Pre-Clinical Stage Products 20
Comparative Analysis 20
Mild Cognitive Impairment Therapeutics – Products under Development by Companies 21
Mild Cognitive Impairment Therapeutics – Products under Investigation by Universities/Institutes 22
Companies Involved in Mild Cognitive Impairment Therapeutics Development 23
Boehringer Ingelheim GmbH 23
AstraZeneca PLC 24
GlaxoSmithKline plc 25
Chiesi Farmaceutici SpA 26
Pfizer Inc. 27
Theratechnologies Inc. 28
Allon Therapeutics Inc. 29
Suven Life Sciences Ltd. 30
Mithridion, Inc. 31
QR Pharma, Inc. 32
Krenitsky Pharmaceuticals Inc. 33
Mild Cognitive Impairment – Therapeutics Assessment 34
Assessment by Monotherapy Products 34
Assessment by Combination Products 35
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 41
davunetide - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Posiphen - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
GSK-933776 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
MCD-386CR - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
tesamorelin acetate - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
TTP-4000 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
CHF-5074 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
HPP854 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
KP-544 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Naltrexone + Marijuana - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
17B-Estradiol - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Tolcapone + Entacapone - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
atomoxetine hydrochloride - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
pregnenolone - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
cannabidiol - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
insulin human - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
minocycline - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Candesartan + Nifedipine + Metoprolol - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 65
Lisinopril + Nifedipine + Metoprolol - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
AZD-5213 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Carboplatin + Sodium Thiosulfate - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Disulfiram + CM - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
ginkgo biloba - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
immune globulin intravenous pentetate - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
minocycline - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
SUVN-501 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
SUVN-507 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
SUVN-901 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
SUVN-976 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Histamine-3 Antagonist - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Drug Acting On Nicotinic Acetylcholine Receptor Alpha-4 Beta-2 For Neuro Degenerative Diseases - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
5-HT4 agonist and Partial agonist - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
BCA-909 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
insulin detemir recombinant - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
PDE-2 Inhibitor - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
DAOI-B - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Mild Cognitive Impairment Therapeutics – Drug Profile Updates 88
Mild Cognitive Impairment Therapeutics – Discontinued Products 99
Mild Cognitive Impairment Therapeutics - Dormant Products 100
Mild Cognitive Impairment – Product Development Milestones 101
Featured News & Press Releases 101
May 17, 2012: Avraham Initiates Phase II Ladostigil Study For Treatment Of Mild Cognitive Impairment 101
Oct 20, 2011: Prana Biotechnology Announces Australian Federal Government Grant To Study Effect Of PBT2 In Ageing Brain 101
Oct 13, 2011: QR Pharma Reports Results From SBIR Grant By NIA/NIH To Study Posiphen And Metabolites In Various Models 102
Apr 20, 2011: Neurokine Selects Clinical Trial Sites For NK-001 Phase II Study 102
Apr 14, 2011: Adeona's Clinical Study Of reaZin Meets Primary Outcomes Of Increasing Serum Zinc And Decreasing Serum Free Copper 103
Mar 03, 2011: Allon Presents Data Of Human Pharmacokinetic Model At Clinical Pharmacology Conference 104
Feb 10, 2011: Allon Granted Key Japanese Patent For Davunetide 105
Feb 03, 2011: Neurokine Signs Contract With Clinical Investigation Group To Initiate Phase II NK-001 Human Clinical Trials In Europe 105
Nov 30, 2010: Aphios Awarded Phase I of Fast Track SBIR Grant from National Institute of Aging for Novel Alzheimer's Disease Nanodrug 106
Oct 06, 2010: Adeona Completes 100% Enrollment In Pivotal Alzheimer’s Disease And Mild Cognitive Impairment Clinical Study 106
Appendix 107
Methodology 107
Coverage 107
Secondary Research 107
Primary Research 107
Expert Panel Validation 107
Contact Us 108
Disclaimer 108

List of Tables
Number of Products Under Development for Mild Cognitive Impairment, H2 2012 11
Products under Development for Mild Cognitive Impairment – Comparative Analysis, H2 2012 12
Number of Products under Development by Companies, H2 2012 14
Number of Products under Investigation by Universities/Institutes, H2 2012 16
Comparative Analysis by Late Stage Development, H2 2012 17
Comparative Analysis by Mid Clinical Stage Development, H2 2012 18
Comparative Analysis by Early Clinical Stage Development, H2 2012 19
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 20
Products under Development by Companies, H2 2012 21
Products under Investigation by Universities/Institutes, H2 2012 22
Boehringer Ingelheim GmbH, H2 2012 23
AstraZeneca PLC, H2 2012 24
GlaxoSmithKline plc, H2 2012 25
Chiesi Farmaceutici SpA, H2 2012 26
Pfizer Inc., H2 2012 27
Theratechnologies Inc., H2 2012 28
Allon Therapeutics Inc., H2 2012 29
Suven Life Sciences Ltd., H2 2012 30
Mithridion, Inc., H2 2012 31
QR Pharma, Inc., H2 2012 32
Krenitsky Pharmaceuticals Inc., H2 2012 33
Assessment by Monotherapy Products, H2 2012 34
Assessment by Combination Products, H2 2012 35
Assessment by Stage and Route of Administration, H2 2012 37
Assessment by Stage and Molecule Type, H2 2012 40
Mild Cognitive Impairment Therapeutics – Drug Profile Updates 88
Mild Cognitive Impairment Therapeutics – Discontinued Products 99
Mild Cognitive Impairment Therapeutics – Dormant Products 100

List of Figures
Number of Products under Development for Mild Cognitive Impairment, H2 2012 11
Products under Development for Mild Cognitive Impairment – Comparative Analysis, H2 2012 12
Products under Development by Companies, H2 2012 13
Products under Investigation by Universities/Institutes, H2 2012 15
Late Stage Products, H2 2012 17
Mid Clinical Stage Products, H2 2012 18
Early Clinical Stage Products, H2 2012 19
Discovery and Pre-Clinical Stage Products, H2 2012 20
Assessment by Monotherapy Products, H2 2012 34
Assessment by Combination Products, H2 2012 35
Assessment by Route of Administration, H2 2012 36
Assessment by Stage and Route of Administration, H2 2012 37
Assessment by Molecule Type, H2 2012 38
Assessment by Stage and Molecule Type, H2 2012 39

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos